{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:26:09Z","timestamp":1787131569501,"version":"build-2736575974"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024591","name":"National Institute of Pharmaceutical Education and Research, Kolkata","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114672","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:46:18Z","timestamp":1769618778000},"page":"114672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mesalamine premix-based delayed release formulation and its efficacy assessment using a 3D in-vitro gut model for inflammatory bowel disease"],"prefix":"10.1016","volume":"392","author":[{"given":"Sunil Kumar","family":"Sah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohare Rahul","family":"Sanjay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makka Krupali","family":"Ashokbhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadeep","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Kaity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114672_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jconrel.2026.114672_bb0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114672_bb0015","first-page":"1","article-title":"Recent advances in mesalamine colonic delivery systems","volume":"6","author":"Bayan","year":"2020","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104011","article-title":"Premix technologies for drug delivery: manufacturing, applications, and opportunities in regulatory filing","volume":"29","author":"Ashokbhai","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.114672_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.18231\/j.joapr.2024.12.2.93.108","article-title":"Modulation of mesalamine release from enteric-coated matrix tablets using natural polysaccharides for loclaized colonic delivery","volume":"12","author":"Sahu","year":"2024","journal-title":"J. Appl. Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114672_bb0030","first-page":"063","article-title":"Considerations in excipient selection for colon-targeted dosage forms","volume":"15","author":"Gunawan","year":"2025","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125062","article-title":"Clinically relevant cell culture model of inflammatory bowel diseases for identification of new therapeutic approaches","volume":"669","author":"Antoine","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0040","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.3390\/biomedicines13112690","article-title":"The vulnerable vascular network: endothelial dysfunction as a central driver of intestinal inflammation\u2014a systematic review","volume":"13","author":"Mih\u0103ilu\u021b\u0103","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.114672_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-013-0315-7","article-title":"Deep remission in inflammatory bowel disease: looking beyond symptoms","volume":"15","author":"Zallot","year":"2013","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jconrel.2026.114672_bb0050","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s13346-023-01461-1","article-title":"A novel Posaconazole oral formulation using spray dried solid dispersion technology: in-vitro and in-vivo study","volume":"14","author":"Patel","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114672_bb0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/scipharm88040052","article-title":"Development and characterization of glimepiride novel solid nanodispersion for improving its oral bioavailability","volume":"88","author":"Qushawy","year":"2020","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0060","doi-asserted-by":"crossref","first-page":"19786","DOI":"10.1039\/D4NR03137G","article-title":"Rebamipide nanocrystal with improved physicomechanical properties and its assessment through bio-mimicking 3D intestinal permeability model","volume":"16","author":"Samim Sardar","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.114672_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/pharmaceutics12010014","article-title":"Spray dried formulations for inhalation\u2014meaningful characterisation of powder properties","volume":"12","author":"J\u00fcptner","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114672_bb0070","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.2147\/DDDT.S176099","article-title":"Glucosamine-paracetamol spray-dried solid dispersions with maximized intrinsic dissolution rate, bioavailability and decreased levels of in vivo toxic metabolites","volume":"12","author":"Abdelhaleem Ali","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2026.114672_bb0075","article-title":"Preparation, advanced characterization, and current regulatory roadmap for pharmaceutical cocrystals","author":"Sah","year":"2025","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.jconrel.2026.114672_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123272","article-title":"Enhanced powder dispersion of dual-excipient spray-dried powder formulations of a monoclonal antibody and its fragment for local treatment of severe asthma","volume":"644","author":"Pan","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121657","article-title":"Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system","volume":"618","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114672_bb0090","first-page":"19","article-title":"Stability and accelerated stability studies of dosage forms","volume":"2","author":"Kashinath","year":"2024","journal-title":"Physico-Chem. Aspects Dosage Forms Biopharm. Recent Future Trends Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125142","article-title":"Targeted delivery of DAPT using dual antibody functionalized solid lipid nanoparticles for enhanced anti-tumour activity against triple negative breast cancer","volume":"670","author":"Kumari","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbrc.2022.12.054","article-title":"Mechanistic crosstalk of extracellular calcium-mediated regulation of maturation and plasticity in human monocytes","volume":"643","author":"Roy","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.114672_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12951-019-0519-6","article-title":"Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides","volume":"17","author":"Hong","year":"2019","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114480","article-title":"A 3D in-vitro biomimicking Caco-2 intestinal permeability model-based assessment of physically modified telmisartan towards an alkalizer-free formulation development","volume":"203","author":"Sah","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0115","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/pharmaceutics12040328","article-title":"Lack of correlation between in vitro and in vivo studies on the inhibitory effects of (\u2212)-Sophoranone on CYP2C9 is attributable to low oral absorption and extensive plasma protein binding of (\u2212)-Sophoranone","volume":"12","author":"Zheng","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114672_bb0120","first-page":"1","article-title":"A collagen gel-coated, aligned nanofiber membrane for enhanced endothelial barrier function","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114672_bb0125","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/adc50e","article-title":"Fabrication of multilayer heterogeneous cell assembly for pathophysiologically relevant 3D in-vitro IBD disease model for high throughput drug screening","volume":"17","author":"Kumari","year":"2025","journal-title":"Biofabrication"},{"key":"10.1016\/j.jconrel.2026.114672_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.639716","article-title":"Development of an advanced multicellular intestinal model for assessing immunomodulatory properties of anti-inflammatory compounds","volume":"12","author":"Marescotti","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/acsbiomaterials.1c01432","article-title":"Macrophage polarization profiling on native and regenerated silk biomaterials","volume":"8","author":"Roy","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2026.114672_bb0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s44164-022-00025-w","article-title":"Interlaboratory comparison of an intestinal triple culture to confirm transferability and reproducibility","volume":"2","author":"K\u00e4mpfer","year":"2022","journal-title":"In vitro models"},{"key":"10.1016\/j.jconrel.2026.114672_bb0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.phme.2013.12.003","article-title":"Validation of stability indicating RP-HPLC method for the estimation of mesalamine in bulk and tablet dosage form","volume":"4","author":"Sahoo","year":"2013","journal-title":"Pharm Methods"},{"key":"10.1016\/j.jconrel.2026.114672_bb0155","first-page":"49","article-title":"A comprehensive review on sustained release matrix tablet: a promising dosage form","volume":"3","author":"Prakhar","year":"2018","journal-title":"Univ. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114672_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.22270\/ujpr.v1i2.R3","article-title":"Formulation and evaluation of finasteride sustained release matrix tablets using different rate controlling polymers","author":"Chibueze","year":"2016","journal-title":"Univ. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114672_bb0165","doi-asserted-by":"crossref","DOI":"10.22270\/ujpr.v3i5.205","article-title":"Development and characterization of direct compressed matrix mini tablets of naproxen sodium","author":"Opeyemi","year":"2018","journal-title":"Univ. J. Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114672_bb0170","first-page":"61","article-title":"Drug dissolution studies of pharmaceutical formulations","volume":"2","author":"Ashokbhai","year":"2024","journal-title":"Physico-Chem. Aspects Dosage Forms Biopharm. Recent Future Trends Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.powtec.2013.06.038","article-title":"Fundamental analysis of particle formation in spray drying","volume":"247","author":"Vicente","year":"2013","journal-title":"Powder Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0180","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.38124\/ijisrt\/25apr1440","article-title":"Advances in spray drying for pharmaceutical formulations: enhancing drug solubility and bioavailability, international journal of innovative science and research technology enhancing drug solubility and bioavailability","volume":"10","author":"Naik","year":"2025","journal-title":"Int. J. Innov. Sci. Res. Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.18231\/j.jpbs.2021.018","article-title":"Enrichment of aqueous solubility and dissolution profile of mesalamine: in vitro evaluation of solid dispersion","volume":"9","author":"Pawar","year":"2021","journal-title":"J. Pharm. Biol. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0190","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.114672_bb0195","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.52711\/0974-360X.2025.00464","article-title":"Development of mesalamine self nanoemulsifying drug delivery system to improve solubility and permeability","volume":"18","author":"Shinde","year":"2025","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0200","article-title":"Revolutionizing colon-targeted drug delivery: the pivotal role of lipid nano-carriers and their transformative modifications","author":"Adidharma Wilie","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.07.011","article-title":"A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system","volume":"321","author":"Dokoumetzidis","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0210","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.ces.2005.02.028","article-title":"Continuous granulation in the pharmaceutical industry","volume":"60","author":"Vervaet","year":"2005","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0215","author":"Kaur"},{"key":"10.1016\/j.jconrel.2026.114672_bb0220","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1021\/acs.molpharmaceut.6b00740","article-title":"Solid-state spectroscopic investigation of molecular interactions between clofazimine and hypromellose phthalate in amorphous solid dispersions","volume":"13","author":"Nie","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0225","first-page":"97","article-title":"Design and characterization of mesalamine loaded nanoparticles for controlled delivery system","volume":"1","author":"Seifirad","year":"2016","journal-title":"Nanomed. Res. J."},{"key":"10.1016\/j.jconrel.2026.114672_bb0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2013.11.001","article-title":"Fundamental aspects of solid dispersion technology for poorly soluble drugs","volume":"4","author":"Huang","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114672_bb0235","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3109\/03639045.2015.1118493","article-title":"Novel self-assembled mesalamine\u2013sucralfate complexes: preparation, characterization, and formulation aspects","volume":"42","author":"Ispas-Szabo","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.102540","article-title":"Lipid-polymer nano core-shell type hybrid system for colon specific drug delivery","volume":"63","author":"Wang","year":"2021","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0245","series-title":"Handbook of Pharmaceutical Excipients","first-page":"333","article-title":"Hypromellose phthalate","author":"Goskonda","year":"2009"},{"key":"10.1016\/j.jconrel.2026.114672_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112937","article-title":"Solid-state analysis of amorphous solid dispersions: why DSC and XRPD may not be regarded as stand-alone techniques","volume":"178","author":"Dedroog","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2026.114672_bb0255","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3329\/dujps.v22i2.69325","article-title":"Design, optimization and in vitro evaluation of Mesalazine 400 mg delayed release tablet for colon specific delivery","volume":"22","author":"Shill","year":"2023","journal-title":"Dhaka Univ. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0260","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijpharm.2015.04.007","article-title":"Systematic identification of thermal degradation products of HPMCP during hot melt extrusion process","volume":"486","author":"Karandikar","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0265","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/17425247.2020.1702643","article-title":"Physical stability of dry powder inhaler formulations","volume":"17","author":"Shetty","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114672_bb0270","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/07373937.2010.485083","article-title":"Moisture sorption isotherms and storage stability of spray-dried yogurt powder","volume":"28","author":"Ko\u00e7","year":"2010","journal-title":"Dry. Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2036.18.s2.1.x","article-title":"Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease","volume":"18","author":"Allgayer","year":"2003","journal-title":"Aliment. Pharm. Therap. Suppl."},{"key":"10.1016\/j.jconrel.2026.114672_bb0280","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3390\/pharmaceutics13101563","article-title":"Re-use of caco-2 monolayers in permeability assays\u2014validation regarding cell monolayer integrity","volume":"13","author":"Pires","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114672_bb0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.vascn.2014.08.002","article-title":"Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations","volume":"70","author":"Jin","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2026.114672_bb0290","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.114672_bb0295","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/jphp.13111","article-title":"Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines","volume":"71","author":"Jarc","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0300","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/03639040701655952","article-title":"In vitro assessment of acyclovir permeation across cell monolayers in the presence of absorption enhancers","volume":"34","author":"Shah","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0305","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4149\/gpb_2013034","article-title":"Transintestinal transport mechanisms of 5-aminosalicylic acid (in situ rat intestine perfusion, Caco-2 cells) and biopharmaceutics classification system","volume":"32","author":"Smetanov\u00e1","year":"2013","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.jconrel.2026.114672_bb0310","series-title":"Oral Drug Absorption: Prediction and Assessment","first-page":"1","author":"Dressman","year":"2016"},{"key":"10.1016\/j.jconrel.2026.114672_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43214-7","article-title":"Validation and characterization of a novel blood\u2013brain barrier platform for investigating traumatic brain injury","volume":"13","author":"Bolden","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114672_bb0320","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrm1357","article-title":"Endothelial cell-cell junctions: happy together","volume":"5","author":"Dejana","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0325","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.5599\/admet.2603","article-title":"Effect of bicarbonate buffer on artificial membrane permeation of drugs: original scientific article","volume":"13","author":"Ishida","year":"2025","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.jconrel.2026.114672_bb0330","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s44164-023-00047-y","article-title":"A human Caco-2-based co-culture model of the inflamed intestinal mucosa for particle toxicity studies","volume":"2","author":"Paul","year":"2023","journal-title":"In vitro models"},{"key":"10.1016\/j.jconrel.2026.114672_bb0335","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.3390\/ijms24087427","article-title":"Development of an inflammation-triggered in vitro \u201cleaky gut\u201d model using Caco-2\/HT29-MTX-E12 combined with macrophage-like THP-1 cells or primary human-derived macrophages","volume":"24","author":"Le","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0340","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2012.10.003","article-title":"Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs","volume":"83","author":"Antunes","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0345","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/BCR.0000000000000396","article-title":"Effects of Mesalamine treatment on gut barrier integrity after burn injury","volume":"37","author":"Cannon","year":"2016","journal-title":"J. Burn Care Res."},{"key":"10.1016\/j.jconrel.2026.114672_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-39401-0","article-title":"Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation","volume":"9","author":"Khare","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114672_bb0355","doi-asserted-by":"crossref","first-page":"16297","DOI":"10.1021\/acsnano.4c05544","article-title":"Mucoadhesive Mesalamine prodrug Nanoassemblies to target intestinal macrophages for the treatment of inflammatory bowel disease","volume":"18","author":"Park","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114672_bb0360","series-title":"Aulton\u2019s Pharmaceutics: The Design and Manufacture of Medicines","author":"Michael","year":"2013"},{"key":"10.1016\/j.jconrel.2026.114672_bb0365","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114672_bb0370","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/B978-0-323-91817-6.00009-7","article-title":"Pharmaceutical packaging: recent trends and challenges","volume":"1","author":"Sah","year":"2024","journal-title":"Dosage Forms Formulat. Developm. Regulat. Recent Future Trends Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0375","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13104-018-3285-x","article-title":"In vitro comparative quality evaluation of different brands of esomeprazole tablets available in selected community pharmacies in Dhaka, Bangladesh","volume":"11","author":"Dulla","year":"2018","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.jconrel.2026.114672_bb0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2015.02.061","article-title":"Validation and applications of an expedited tablet friability method","volume":"484","author":"Osei-Yeboah","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114672_bb0385","doi-asserted-by":"crossref","DOI":"10.1201\/b15445","article-title":"Oral drug absorption: prediction and assessment","author":"Dressman","year":"2000","journal-title":"Oral Drug Absorpt."},{"key":"10.1016\/j.jconrel.2026.114672_bb0390","article-title":"Advances in the development of amorphous solid dispersions: the role of polymeric carriers","volume":"18","author":"Zhang","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0395","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/17425247.2013.821978","article-title":"pH- and ion-sensitive polymers for drug delivery","volume":"10","author":"Yoshida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114672_bb0400","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/pharmaceutics14020291","article-title":"In vitro methodologies for evaluating colon-targeted pharmaceutical products and industry perspectives for their applications","volume":"14","author":"Garc\u00eda","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114672_bb0405","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2017.09.037","article-title":"New mesalamine polymeric conjugate for controlled release: preparation, characterization and biodistribution study","volume":"111","author":"Cesar","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114672_bb0410","article-title":"Optimized mesalamine-loaded polyelectrolyte complex nanoparticles for targeted colon delivery in inflammatory bowel disease treatment: a central composite design approach","volume":"8","author":"Fatima","year":"2025","journal-title":"Next Mater."},{"key":"10.1016\/j.jconrel.2026.114672_bb0415","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s11095-005-5376-3","article-title":"Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model","volume":"22","author":"Kesisoglou","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114672_bb0420","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/acsfoodscitech.4c00493","article-title":"Liposomal freight and their advanced microstructure characterization techniques for food and nutraceutical delivery","volume":"4","author":"Aggarwal","year":"2024","journal-title":"ACS Food Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114672_bb0425","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.12.054","article-title":"Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis","volume":"138","author":"Sandborn","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:35:59Z","timestamp":1787128559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":84,"alternative-id":["S0168365926000738"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114672","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesalamine premix-based delayed release formulation and its efficacy assessment using a 3D in-vitro gut model for inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114672"}}